Key Takeaways
- Supply chain, not demand, broke the quarter: Egypt operations were idle for most of March because raw materials were stuck at transhipment points, and sudden freight rate spikes blocked RoW dispatches until repricing was renegotiated.
- India and Americas are the offsetting engines: India grew 8% on GST rationalization and steady Tier 1/non-Tier 1 demand, while the Americas strengthened sequentially after tariff reversals restarted the U.S. specialty pipeline.
- AMET has structurally reset lower: Volumes have dropped from 90,000 to 60,000 metric tonnes per annum as local backward-integrated players and global customer share losses combined with inflation-driven consumption destruction in Egypt and Turkey.
- Q1 guidance is specific but conditional: Management expects volumes at the higher end of 6–8% and EBITDA at the higher end of ₹19,000–21,000 per metric tonne, provided the current environment does not worsen.
- What to watch next quarter: Whether Egypt runs uninterrupted through May and June, whether the RoW backlog clears without further freight repricing fights, and whether India’s 8–10% growth holds if energy prices or monsoons dent demand.
Supply Chain Disruption
- Egypt: a March washout, not a demand problem: The plant was idle for most of March because inbound raw materials were stuck at transhipment points and outbound shipments could not move; operations were restored to a significantly superior level from mid-April.
- Freight spikes froze RoW dispatches: Orders to Latin America and Europe were ready but could not be shipped because of a sudden increase in freight rates; management spent a good portion of March renegotiating repricing with customers, and the backlog is now being cleared.
- Feedstock prices surged across the board: The West Asia war drove a sharp, simultaneous escalation across input raw materials, with petrochemical base feedstocks rising much more than oleochemical feedstocks; this exerted repricing pressure at major customer levels and impacted Q4 volumes.
- Supply-side pain, but demand intact: Unlike FY22–23 when supply was constrained but demand was rising, the current situation has supply impacted while demand, as of now, remains intact; the concern is whether the energy situation eventually hits consumer discretionary spending.
Natarajan: "The question here today is not about whether oleochemical has gone up because that was the fact till, say, last quarter. Now everything has gone up significantly. In fact, petrochemical prices -- base feedstocks have gone up much more than the oleochemical feedstock prices."
Regional Performance
| Region | Trend | Commentary |
|---|---|---|
| India | ▲ Resilient | 8% growth driven by GST rationalization; Tier 1 reformulation pressure in Performance segment fully offset by non-Tier 1 and D2C accounts on a year-to-date basis. |
| Americas | ▲ Bright spot | Sequential volume improvement over Q3 after tariff-related clarity and partial reversals; U.S. specialty pipeline reinitiated, and TRI-K premium specialty business performed consistently better. |
| AMET | ▼ Sharp decline | 15% degrowth was majorly supply-led from Egypt idling; structurally, volumes have reset from 90,000 to 60,000 metric tonnes per annum on local competition, global customer share losses, and inflation-driven consumption destruction in Egypt and Turkey. |
| RoW | ▼ Delayed, not lost | Volume shortfall driven by freight-rate-driven shipment delays to Europe and LatAm and cautious customer buying; backlog is clearing as repricing negotiations conclude. |
- AMET has probably bottomed: Management believes the region should only improve from here, starting from coming quarters, though the ability to place volumes into other markets is limited by credit risk and sanctions.
- India’s growth carries a condition: The 8–10% expectation holds if the monsoon does not impact demand and energy prices do not force customers to cut production and reduce inventory; grammage cuts as a price-pass-through mechanism are not yet visible.
Natarajan: "I don't have a tailwind to take it to 90,000, but there's nothing that is going to not allow me to grow at a reasonable rate from this base of 60,000."
Product & Strategy Updates
- Galsoft Lumithic launched: A next-generation, self-thickening, amino acid-based mild surfactant unveiled at in-cosmetics Paris; targets baby care, feminine hygiene, scalp care and anti-acne solutions with low-pH compatibility.
- Alternative product already in market: The company is already producing and selling the alternative product that had been taking market share in India; supply-side changes have shifted the dynamic, and management intends to use flexibility to regain volume share.
- 2030 vision: on track in Specialty, lagging in Wellness: Phase 1 products including Lumithic have been launched and the production pipeline built, leveraging existing specialty ingredients capacities; the Wellness segment has not made expected progress and management is not satisfied.
- Capex monetization begins now: The major portion of the ₹480 crores capex was commissioned only in the last 1.5 years, with the bulk in the Specialty Ingredients segment; some benefits will start reflecting this year and momentum will build.
- Revenue from 2030 initiatives is backloaded: Meaningful contribution will start in FY26–27, with a good portion in FY28–29 and FY29–30; FY27–28 will also begin to reflect it.
- Long-term specialty mix ambition: By 2031, management sees the Performance-to-Specialty mix likely in the zone of 60–40 or 65–35.
Margins & Cost Management
- EBITDA held up on pass-through and mix: Performance was supported by effective pass-through of raw material and freight cost increases to customers, an improved specialty mix in Q4 after U.S. tariff reversals, consistent better performance from the TRI-K business, and disciplined cost control across operations and subsidiaries.
- Raw material situation remains tight: Ethylene oxide and sulfur supply is not comfortable, but vendor partnerships are managing the supply side; prices have gone up significantly.
- No panic buying in India: Buyers were ensuring security of supply rather than panic-buying; high-season months run January through August/September, and customers are ramping up production.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Q1 volume growth | Higher end of 6% to 8% range | Q1 FY27 (45 days remaining at time of call) |
| Q1 EBITDA per metric tonne | Higher end of ₹19,000 to ₹21,000 band | Q1 FY27 |
| Full-year performance | Deliver at Q1 run-rate levels | FY27, provided current scenario does not worsen |
| India growth | 8% to 10% | Continuing into Q1, subject to monsoon and energy prices not denting demand |
| AMET improvement | Grow at a reasonable rate from the 60,000 MT base; supply-side factors to improve significantly | Q1 FY27 and coming quarters |
| Egypt operations | Run uninterrupted at significantly superior levels | May and June 2026 |
| Americas acceleration | Results to start reflecting | Coming quarters |
| Capex | No new growth capex commitments; only routine brownfield or replacement capex | FY27 |
| Specialty mix | 60–40 or 65–35 (Performance vs Specialty) | By 2031 |
Natarajan: "I don't want to mislead because there's no way that I can — because the way things are, I'm just looking at the quarter 1."
Key Metrics
| Metric | Q4 FY26 |
|---|---|
| Revenue | ₹498 cr (Specialty Care Products top line), flat QoQ |
| EBITDA | ₹122 cr, compared to ₹135 cr in Q4 FY25 |
| EBITDA per metric ton | ₹20,114, vs ₹21,715 in Q4 FY25 |
| Full-year FY26 EBITDA per metric ton | ~₹19,000 |
| Q1 FY27 volume growth guidance | Higher end of 6% to 8% |
| Q1 FY27 EBITDA per metric ton guidance | Higher end of ₹19,000 to ₹21,000 |
| India volumes growth | 8% YoY |
| India performance segment volumes growth | 3% YoY |
| India specialty volumes growth | More than 27% YoY |
| Specialty Care Products annual growth | 27% |
| AMET region volumes decline | 15% YoY, majorly supply-led |
| Rest of world volumes decline | 7% YoY in Q4, 4% growth on full year basis |
| AMET Jan-Feb growth rate | ~2% to 3% (per management estimate) |
| Capex last 3 years | ~₹480 cr, bulk on Specialty Ingredients |
| Maintenance capex | Not more than ₹20-30 cr per year |